Changes in biologic phenotype of human immunodeficiency virus during treatment of patients with didanosine

Journal of Infectious Diseases

Volumn 173, Issue 5, 1996, Pages 1092-1096

  Zheng, N N ^c   McQueen, P W ^c   Hurren, L ^c   Evans, L A ^b   Law, M G ^c   Forde, S ^c   Barker, S ^c   Cooper, D A ^a   Delaney, S F ^c  

^a ST VINCENT S HOSPITAL   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; DIDANOSINE; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS TYPING;

EID: 0029898728     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/173.5.1092     Document Type: Article

References (28)

1. York-Higgins D, Cheng-Mayer C, Bauer D, Levy JA, Dina D. Human immunodeficiency virus type 1 cellular host range, replication, and cytopathicity are linked to the envelope region of the viral genome. J Virol 1990;64:4016-20.
2. Boucher CAB, Lange JMA, Miedema FF, et al. HIV-1 biological phenotype and the development of zidovudine resistance in relation to disease progression in asymptomatic individuals during treatment. AIDS 1992;6:1259-64.
3. De Jong M, Boucher C. Syncytia formation and HIV load. Transcript 1993;31:9-12.
4. + cell depletion and progression to AIDS. Ann Intern Med 1993;118:681-8.
5. St. Clair MH, Martin JL, Tudor-Williams G, et al. Zidovudine resistance, syncytium-inducing phenotype, and HIV disease progression in a case-control study. The VA Cooperative Study Group. J Acquir Immune Defic Syndr 1993;6:891-7.
6. Kahn JO, Lagakos SW, Richman DD, et al. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. N Engl J Med 1992;327:581-7.
7. Richman DD. Resistance, drug failure and disease progression. AIDS Res Hum Retroviruses 1994;10:901-5.
8. Tsang ML, Evans LA, McQueen P, et al. Neutralizing antibodies against sequential autologous human immunodeficiency virus type 1 isolates after seroconversion. J Infect Dis 1994;170:1141-7.
9. Tersmette M, de Goede REY, Al BJM, et al. Differential syncytium-inducing capacity of human immunodeficiency virus isolates: frequent detection of syncytium-inducing isolates in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. J Virol 1988;62:2026-32.
10. Yerly S, Kaiser L, Baumberger C, Hirschel B, Perrin LH. Early and prolonged decrease of viremia in HIV-1-infected patients treated with didanosine. J Acquir Immune Defic Syndr Hum Retrovirol 1995;8:358-64.
11. Jurriaans S, Van Gemen B, Weverling GJ, et al. The natural history of HIV-1 infection: are virus load and virus phenotype independent determinants of clinical course? Virology 1994;204:223-33.
12. Japour AJ, Fiscus SA, Arduino JM, Mayers DL, Reichelderfer PS, Kuritzkes DR. Standardized microtiter assay for determination of syncytium-inducing phenotypes of clinical human immunodeficiency virus type 1 isolates. J Clin Microbiol 1994;32:2291-4.
13. Richman DD, Bozzette SA. The impact of syncytium-inducing phenotype of human immunodeficiency virus on disease progression. J Infect Dis 1994;169:968-74.
14. Bozzette SA, McCutchan JA, Spector SA, Wright B, Richman DD. A cross-sectional comparison of persons with syncytium-and non-syncytium-inducing human immunodeficiency virus. J Infect Dis 1993;168:1374-9.
15. Fenyo EM, Morfeldt-Manson L, Chiodi F, et al. Distinct replicative and cytopathic characteristics of human immunodeficiency virus isolates. J Virol 1988;62:4414-9.
16. Asjo B, Morfeldt-Manson L, Albert J, et al. Replicative capacity of human immunodeficiency virus from patients with varying severity of HIV infection. Lancet 1986;2:660-2.
17. Femandez-Larsson R, Srivastava KK, Lu S, Robinson HL. Replication of patient isolates of human immunodeficiency virus type 1 in T cells: a spectrum of rates and efficiencies of entry. Proc Natl Acad Sci USA 1992;89:2223-6.
18. Hogervorst E, de Jong J, van Wijk A, et al. Insertion of primary syncytium-inducing (SI) and non-SI envelope V3 loops in human immunodeficiency virus type 1 (HIV-1) LAI reduces neutralization sensitivity to autologous, but not heterologous, HIV-1 antibodies. J Virol 1995;69:6342-51.
19. De Jong JJ, De Ronde A, Keulen W, Tersmette M, Goudsmit J. Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution. J Virol 1992;66:6777-80.
20. De Jong JJ, Goudsmit J, Keulen W, et al. Human immunodeficiency virus type 1 clones chimeric for the envelope V3 domain differ in syncytium formation and replication capacity. J Virol 1992;66:757-65.
21. Fouchier RAM, Groenink M, Kootstra NA, et al. Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol 1992;66:3183-7.
22. Mammano F, Salvatori F, Ometto L, Panozzo M, Chieco-Bianchi L, De Rossi A. Relationship between the V3 loop and the phenotype of human immunodeficiency viras type 1 (HIV-1) isolates from children perinatally infected with HIV-1. J Virol 1995;69:82-92.
23. Groenick M, Fouchier RAM, Broersen S, et al. Relation of phenotype evolution of HIV-1 to envelope V2 configuration Science. 1993;260:1513-6.
24. Andeweg AC, Leeflang P, Osterhaus ADME, Bosch ML. Both the V2 and V3 regions of the human immunodeficiency virus type 1 surface glycoprotein functionally interact with other envelope regions in syncytium formation. J Virol 1993;67:3232-9.
25. Freed EO, Martin MA. Evidence for a functional interaction between the V1/V2 and C4 domains of human immunodeficiency virus type 1 envelope glycoprotein gp120. J Virol 1994;68:2503-12.
26. Vavro CL, St. Clair M, Pennington KN, Valentine M, McKinney RE. A novel in vitro H1V property in pediatric isolates, [abstract]. In: Proceedings of the Third International Workshop on H1V Drug Resistance (Kauai, Hawaii), 1994:53.
27. Delforge ML, Liesnard C, Debaisieux L, Tchetcheroff M, Farber CM, Van Vooren JP. In vivo inhibition of syncytium-inducing variants of HIV in patients treated with didanosine. AIDS 1995;9:89-90.
28. Karlsson A, Parsmyr K, Sandstrom E, Fenyo EM, Albert J. MT-2 cell tropism as prognostic marker for disease progression in human immunodeficiency virus type 1 infection. J Clin Microbiol 1994;32:364-70.